Conference Coverage
Latest News
Jun 16, 2026 | News
Study Finds Psoriasis Patients Trust Topical Therapies Less Than Those With AD
Avalo Therapeutics Announces Long-Acting Anti-IL-1β Antibody Program With Potential Applications in HS
Jun 16, 2026
Single-Dose IL-2 Fusion Protein Shows Hair Regrowth Signal in Early Trial
Jun 16, 2026
First HA Injectable for Neck Wrinkles Cleared by FDA
Jun 16, 2026
Oral STAT6 Degrader KT-621 Delivers Biologics-Like Efficacy in Moderate to Severe AD
Jun 16, 2026
Videos
Advertisement
Shorts
0:36
Expanding Access and Promoting Purpose in Dermatology
a day ago
by
Amy Snow, PA-C
0:39
How to Stop Patients from Following Unsafe Skin Care Trends
6 days ago
by
Suneel Chilukuri, M.D.
0:41
Bimatrizinol Becomes First New US Sunscreen Ingredient in 20 Years
6 days ago
by
Christopher G. Bunick, MD, PhD
0:45
Showing Patients Evidence of Sun Damage
7 days ago
by
Deborah S. Sarnoff, MD
0:35
Afamelanotide That Boosts Skin Photoprotection
8 days ago
by
Elizabeth Buzney, MD
0:23
Why Not All Microneedling Pens Are The Same
12 days ago
by
Michael Gold, MD
1:00
Resources for Clinicians From the Melanoma Research Foundation
13 days ago
by
Miriam Pomerantz Kadosh, MSW, LCSW
0:57
Soquelitinib May Offer New Oral Treatment for Patients With AD
14 days ago
by
Albert Chiou, MD, MBA
0:43
Why Rare Diseases Like EPP Are Frequently Misdiagnosed
15 days ago
by
Elizabeth Buzney, MD
1:00
Stop Calling Them Side Effects: Pro-Tips for Photodynamic Therapy
18 days ago
by
Neal Bhatia, MD
GEP-Guided Treatment for Melanoma & SCC Management
New Insights in Management of Moderate Hidradenitis Suppurativa
Discover Dermatology Times NP/PA Connect™!
Personalizing Treatment for Difficult Atopic Dermatitis Cases
Connect With Dermatology Times® Wherever You Scroll
Podcasts
Dermatology Times Digital Edition
Data from the BroADen trial suggest that targeting STAT6 through protein degradation may offer a novel oral approach to controlling type 2 inflammation in atopic dermatitis.
Because BCC and cSCC have high tumor mutational burdens driven by UV-induced DNA damage, they are particularly well suited to immune checkpoint inhibition.
In clinical practice, digital twins could predict how individual patients respond to treatments based on factors such as genetics, skin barrier function, and lifestyle patterns.
A phase 2 clinical trial found that topical ruxolitinib cream showed promising efficacy and safety in patients with mild to moderate hidradenitis suppurativa.
The June issue of Dermatology Times highlights the latest advances in skin cancer, psoriasis, atopic dermatitis, hidradenitis suppurativa, and emerging dermatology technologies.
Learn more about the in-depth topics covered in the May 2026 print issue of Dermatology Times.
Hadar Lev-Tov, MD, said one of the most rewarding aspects of treating HS is hearing patients say, “Doctor, you saved my life.”
Employment contracts can have enormous financial and career consequences, yet many clinicians review them too casually before signing.
Dermatologists are increasingly integrating AI into clinical workflows, though many still use it primarily as a search tool rather than a true care-support system.
Phase 3 data presented at AAD 2026 showed that amlitelimab significantly improved skin clearance and disease severity in patients aged 12 years and older with moderate to severe atopic dermatitis.
Continuing Medical Education
All News
Advertisement
Advertisement
Cosibelimab joins cemiplimab and pembrolizumab as a first-line option for advanced cSCC unsuitable for curative surgery or radiation.
IL-4Rα blocker stapokibart cleared chronic spontaneous urticaria and improved quality of life after omalizumab failure in a 44-year-old female patient.
SkinJect demonstrated 64% clinical clearance and 55% complete histological response in a phase 2 study of nodular BCC patients.
Because BCC and cSCC have high tumor mutational burdens driven by UV-induced DNA damage, they are particularly well suited to immune checkpoint inhibition.
Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.
Does this structured nighttime skin care routine actually work or is it just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.
In clinical practice, digital twins could predict how individual patients respond to treatments based on factors such as genetics, skin barrier function, and lifestyle patterns.
The review emphasizes that psychological stress can influence inflammatory pathways involved in CSU, potentially worsening disease activity.
Every week, we cut through the noise to bring clinicians the trial results, approvals, and emerging therapies that are actually moving the needle.
A phase 2 clinical trial found that topical ruxolitinib cream showed promising efficacy and safety in patients with mild to moderate hidradenitis suppurativa.
Advertisement
More than 35% of zasocitinib-treated patients reached complete skin clearance at week 16, with treatment curve separation emerging as early as week 8.
Findings support ongoing pharmacovigilance monitoring of GLP-1 receptor agonists for hair loss, particularly as semaglutide and tirzepatide use continues to expand.
FDA clears lebrikizumab (EBGLYSS) every-8-week maintenance dosing for moderate to severe atopic dermatitis, reducing maintenance injections to as few as 6 per year.
This review of the latest dermatological studies includes insights on a mobile AI platform for skin disease prescreening, COVID-19 outcomes in PsO patients on biologics, i-PRF) and laser therapy for facial rejuvenation, and more.
Meta-analysis finds azithromycin pulse therapy matches doxycycline for moderate to severe acne, with fewer GI adverse events and less photosensitivity.
Advertisement
Advertisement
Trending on Dermatology Times
1
Social Media Mythbusters: Skin Cycling
2
What Dermatologists Need to Know About the First New Sunscreen Ingredient in Decades
3
Multidisciplinary Care Anchors Treatment of Advanced cSCC
4
Stapokibart Successfully Treats Refractory CSU After Omalizumab Failure in New Case Report
5